DBV Technologies S.A. (NASDAQ:DBVT) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have been assigned a consensus rating of “Moderate Buy” from the ten analysts that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $35.3750.

A number of brokerages recently weighed in on DBVT. Wall Street Zen upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a research note on Friday, November 28th. Zacks Research raised shares of DBV Technologies from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. HC Wainwright set a $40.00 price objective on shares of DBV Technologies in a research note on Thursday, December 18th. Guggenheim restated a “buy” rating and issued a $51.00 target price (up from $35.00) on shares of DBV Technologies in a research report on Wednesday, December 17th. Finally, Cantor Fitzgerald set a $48.00 target price on shares of DBV Technologies in a research note on Wednesday, December 17th.

DBV Technologies Price Performance

DBVT opened at $20.78 on Tuesday. The stock’s 50 day moving average price is $16.67 and its 200 day moving average price is $13.16. The stock has a market cap of $834.44 million, a P/E ratio of -4.02 and a beta of -1.17. DBV Technologies has a 12 month low of $3.80 and a 12 month high of $26.18.

Insider Activity

In related news, major shareholder Bpifrance Epic sold 1,292,103 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $4.19, for a total transaction of $5,413,911.57. Following the transaction, the insider owned 7,303,369 shares of the company’s stock, valued at approximately $30,601,116.11. This trade represents a 15.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.44% of the company’s stock.

Institutional Trading of DBV Technologies

Several institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC boosted its holdings in shares of DBV Technologies by 38.4% during the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after buying an additional 744 shares during the period. New York State Common Retirement Fund bought a new stake in shares of DBV Technologies during the 3rd quarter worth $34,000. Two Sigma Investments LP acquired a new position in shares of DBV Technologies during the third quarter worth $167,000. Citadel Advisors LLC acquired a new stake in DBV Technologies during the 3rd quarter worth approximately $220,000. Finally, DLD Asset Management LP bought a new position in shares of DBV Technologies during the third quarter worth about $250,000. 71.74% of the stock is currently owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.